IPP Bureau
Anova launches AI-powered patient matching platform to speed clinical trial enrollment
By IPP Bureau - December 16, 2025
Clinical trial enrollment has long been a bottleneck in drug development
Caplin Point Laboratories’ injectables facility completes INVIMA audit successfully
By IPP Bureau - December 15, 2025
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
Indoco receives EIR from the USFDA for its API manufacturing facility at Patalganga
By IPP Bureau - December 15, 2025
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
Eiko LifeSciences to acquire 51% stake in SSM Formulations
By IPP Bureau - December 15, 2025
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
Anil Koul joins Mankind Pharma as Group Chief Scientific Officer
By IPP Bureau - December 15, 2025
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
Akums launches advanced Gabapentin ER for PHN management with RetenEx technology
By IPP Bureau - December 15, 2025
Thermo Fisher Scientific appoints Anoopa Menon as Director
By IPP Bureau - December 14, 2025
In her previous roles, Menon led significant digital transformation efforts, implementing predictive analytics, automation
Novartis appoints Vrinda Taneja as Director – People & Organisation, International India
By IPP Bureau - December 14, 2025
Her journey includes leading HR for large and diverse teams across sales, marketing, corporate functions, and R&D
Emcure Pharmaceuticals appoints Barnona Basu as Director – Marketing (India)
By IPP Bureau - December 14, 2025
Biocon Biologics strikes deal to sell its version of the eye drug Aflibercept worldwide
By IPP Bureau - December 14, 2025
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
FDA completes inspection of SMS Pharma’s Vizag facility
By IPP Bureau - December 14, 2025
The inspection concluded with one minor observation in Form 483
Lilly drug cuts risk of cancer progression, extends survival in advanced breast cancer trial
By IPP Bureau - December 13, 2025
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
EMA backs higher-dose Wegovy, clearing path for greater weight loss option in Europe
By IPP Bureau - December 13, 2025
EMA backs Eylea 8 mg for retinal vein occlusion
By IPP Bureau - December 13, 2025
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
Merck wins key EU backing to expand use of PAH Drug WINREVAIR
By IPP Bureau - December 13, 2025
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
